Opendata, web and dolomites

SPIDIA4P SIGNED

SPIDIA for Personalized Medicine - Standardisation of generic Pre-analytical procedures for In-vitro DIAgnostics for Personalized Medicine

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 SPIDIA4P project word cloud

Explore the words cloud of the SPIDIA4P project. It provides you a very rough idea of what is the project "SPIDIA4P" about.

allowed    reunites    stakeholder    transport    standardisation    quality    industry    balanced    education    collection    stratification    additional    data    applicable    extra    biomolecules    counselling    cen    impacts    personalised    standards    coming    private    external    guidelines    preservation    survey    empowered    tackle    personalized    biomedical    coordinate    vitro    organisation    limited    international    19    eqa    ing    insufficient    spida4p    obtain    smes    foci    spidia4p    action    profiles    medicine    iso    workflow    samples    validation    diagnostics    discovery    22    pan    public    involvements    storage    workflows    training    proposes    biobanks    patients    official    progress    generate    moment    diagnosis    closely    compromised    unreliable    molecular    analytical    post    maximise    disease    corresponding    assurance    improvements    outcome    diagnostic    cellular    specifications    schemes    patient    prognosis    biomarker    serving    portfolio    impossible   

Project "SPIDIA4P" data sheet

The following table provides information about the project.

Coordinator
QIAGEN GMBH 

Organization address
address: QIAGEN STRASSE 1
city: HILDEN
postcode: 40724
website: www.qiagen.com

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Project website http://www.spidia.eu/
 Total cost 2˙079˙053 €
 EC max contribution 1˙999˙972 € (96%)
 Programme 1. H2020-EU.3.1.6. (Health care provision and integrated care)
 Code Call H2020-SC1-2016-RTD
 Funding Scheme CSA
 Starting year 2017
 Duration (year-month-day) from 2017-01-01   to  2020-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    QIAGEN GMBH DE (HILDEN) coordinator 372˙831.00
2    DIN DEUTSCHES INSTITUT FUER NORMUNG E.V. DE (BERLIN) participant 199˙625.00
3    MEDIZINISCHE UNIVERSITAT GRAZ AT (GRAZ) participant 158˙318.00
4    LUXEMBOURG INSTITUTE OF HEALTH LU (LUXEMBOURG) participant 152˙500.00
5    ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM NL (ROTTERDAM) participant 118˙750.00
6    UNIVERSITA DEGLI STUDI DI FIRENZE IT (Florence) participant 102˙875.00
7    TECHNISCHE UNIVERSITAET MUENCHEN DE (MUENCHEN) participant 100˙875.00
8    BIOBANKS AND BIOMOLECULAR RESOURCES RESEARCH INFRASTRUCTURE CONSORTIUM (BBMRI-ERIC) AT (GRAZ) participant 100˙673.00
9    CAMBRIDGE PROTEIN ARRAYS LTD UK (CAMBRIDGE) participant 97˙000.00
10    FUNDACIO CENTRE DE REGULACIO GENOMICA ES (BARCELONA) participant 88˙750.00
11    UNIVERSITA DEGLI STUDI DI TRIESTE IT (TRIESTE) participant 84˙750.00
12    INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE FR (PARIS) participant 82˙750.00
13    UNIVERSITA DEGLI STUDI DI TORINO IT (TORINO) participant 78˙375.00
14    TATAA BIOCENTER AB SE (GOTEBORG) participant 75˙875.00
15    LGC LIMITED UK (TEDDINGTON) participant 73˙398.00
16    CONSORZIO INTERUNIVERSITARIO RISONANZE MAGNETICHE DI METALLO PROTEINE IT (FIRENZE) participant 61˙375.00
17    FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI IT (Milan) participant 51˙250.00
18    INIVATA LIMITED UK (CAMBRIDGE) participant 0.00
19    PREANALYTIX GMBH CH (HOMBRECHTIKON) participant 0.00

Map

 Project objective

Molecular in vitro diagnostics and biomedical research have allowed great progress in personalised medicine but further progress is limited by insufficient guidelines for pre-analytical workflow steps (sample collection, preservation, storage, transport, processing etc.) as well as by insufficient quality assurance of diagnostic practice. This allows using compromised patients’ samples with post collection changes in cellular and extra-cellular biomolecules’ profiles thus often making diagnostic test results unreliable or even impossible. To tackle this, SPIDA4P aims to generate and implement a comprehensive portfolio of 22 pan-European pre-analytical CEN/Technical Specifications and ISO/International Standards, addressing the important pre-analytical workflows applied to personalized medicine. These will also applicable to biomarker discovery, development and validation as well as to biobanks. Corresponding External Quality Assurance (EQA) Schemes will be developed and implemented as well, aiming to survey the resulting quality of samples and diagnostic practice. SPIDIA4P will ensure stakeholder organisations involvements as well as training, education, and counselling as additional major foci of the project. The consortium will closely coordinate with large European public research consortia to obtain access to research and validation studies data serving as evidence for the new standards developments and achieved improvements of diagnosis, patient stratification and prognosis of disease outcome. At this crucial moment in the development of personalised medicine, SPIDIA4P proposes a coordination and support action that reunites 19 highly experienced partners in international standardisation for in vitro diagnostics, coming from private industry including SMEs, public institutions and from one official European Standards Organisation. This strong consortium is balanced and empowered to maximise the impacts of in vitro diagnostics on personalised medicine.

 Deliverables

List of deliverables.
Newsletter of SPIDIA4P (M12) Websites, patent fillings, videos etc. 2020-03-17 14:15:00
Definition of the communication campaign and reviewed (M12) Documents, reports 2020-03-17 14:15:00
Statistics, summary of incidents and measures taken published in the public domain (M18) Documents, reports 2020-03-17 14:15:00
Sub section for SPIDIA4P established on the SPIDIA website Websites, patent fillings, videos etc. 2020-03-17 14:15:00

Take a look to the deliverables list in detail:  detailed list of SPIDIA4P deliverables.

 Publications

year authors and title journal last update
List of publications.
2017 Marika Doucet, Karl Friedrich Becker, Jens Björkman, Jacques Bonnet, Bruno Clément, Maria-Grazia Daidone, Charles Duyckaerts, Gilles Erb, Helmuth Haslacher, Paul Hofman, Berthold Huppertz, Christophe Junot, Joakim Lundeberg, Andres Metspalu, Marialuisa Lavitrano, Jan-Eric Litton, Helen M. Moore, Manuel Morente, Ben-Youssef Naimi, Uwe Oelmueller, Bill Ollier, Barbara Parodi, Liangliang Ruan, Gior
Quality Matters: 2016 Annual Conference of the National Infrastructures for Biobanking
published pages: 270-276, ISSN: 1947-5535, DOI: 10.1089/bio.2016.0053
Biopreservation and Biobanking 15/3 2020-03-17
2019 P.H.J. Riegman, K.F. Becker, K. Zatloukal, M. Pazzagli, U. Schröder, U. Oelmuller
How standardization of the pre-analytical phase of both research and diagnostic biomaterials can increase reproducibility of biomedical research and diagnostics
published pages: 35-40, ISSN: 1871-6784, DOI: 10.1016/j.nbt.2019.06.007
New Biotechnology 53 2020-03-17
2019 Veronica Ghini, Deborah Quaglio, Claudio Luchinat, Paola Turano
NMR for sample quality assessment in metabolomics
published pages: 25-34, ISSN: 1871-6784, DOI: 10.1016/j.nbt.2019.04.004
New Biotechnology 52 2020-03-17
2020 Heimo Müller, Georges Dagher, Martina Loibner, Cornelia Stumptner, Penelope Kungl, Kurt Zatloukal
Biobanks for life sciences and personalized medicine: importance of standardization, biosafety, biosecurity, and data management
published pages: 45-51, ISSN: 0958-1669, DOI: 10.1016/j.copbio.2019.12.004
Current Opinion in Biotechnology 65 2020-03-17
2018 Michael J. Taussig, Cláudia Fonseca, James S. Trimmer
Antibody validation: a view from the mountains
published pages: 1-8, ISSN: 1871-6784, DOI: 10.1016/j.nbt.2018.08.002
New Biotechnology 45 2020-03-17
2019 Georges Dagher, Karl-Friedrich Becker, Serena Bonin, Carole Foy, Stefania Gelmini, Mikael Kubista, Penelope Kungl, Uwe Oelmueller, Helen Parkes, Pamela Pinzani, Peter Riegman, Ulrike Schröder, Cornelia Stumptner, Paola Turano, Robert Sjöback, Andrea Wutte, Kurt Zatloukal
Pre-analytical processes in medical diagnostics: New regulatory requirements and standards
published pages: 121-125, ISSN: 1871-6784, DOI: 10.1016/j.nbt.2019.05.002
New Biotechnology 52 2020-03-17
2019 Cornelia Stumptner, Daniela Pabst, Martina Loibner, Christian Viertler, Kurt Zatloukal
The impact of crosslinking and non-crosslinking fixatives on antigen retrieval and immunohistochemistry
published pages: 69-83, ISSN: 1871-6784, DOI: 10.1016/j.nbt.2019.05.003
New Biotechnology 52 2020-03-17
2020 Serena Bonin, Giorgio Stanta
Pre-analytics and tumor heterogeneity
published pages: 30-35, ISSN: 1871-6784, DOI: 10.1016/j.nbt.2019.09.007
New Biotechnology 55 2020-03-17
2020 Olga Kofanova, Camille Bellora, Sonia Garcia Frasquilho, Laurent Antunes, Gael Hamot, Conny Mathay, Kathleen Mommaerts, Arnaud Muller, Brian DeWitt, Fay Betsou
Standardization of the preanalytical phase of DNA extraction from fixed tissue for next-generation sequencing analyses
published pages: 52-61, ISSN: 1871-6784, DOI: 10.1016/j.nbt.2019.07.005
New Biotechnology 54 2020-03-17
2019 Laura Annaratone, Caterina Marchiò, Anna Sapino
Tissues under-vacuum to overcome suboptimal preservation
published pages: 104-109, ISSN: 1871-6784, DOI: 10.1016/j.nbt.2019.05.007
New Biotechnology 52 2020-03-17
2019 Wim Ammerlaan, Fay Betsou
Biospecimen Science of Blood for cfDNA Genetic Analyses
published pages: 9-15, ISSN: 2167-485X, DOI: 10.1007/s40139-019-00193-7
Current Pathobiology Reports 7/2 2020-03-17
2018 Kurt Zatloukal, Cornelia Stumptner, Penelope Kungl, Heimo Mueller
Biobanks in personalized medicine
published pages: 265-273, ISSN: 2380-8993, DOI: 10.1080/23808993.2018.1493921
Expert Review of Precision Medicine and Drug Development 3/4 2020-03-17
2017 Martina Loibner, Lisa Oberauner-Wappis, Christian Viertler, Daniel Groelz, Kurt Zatloukal
Protocol for HER2 FISH Using a Non-cross-linking, Formalin-free Tissue Fixative to Combine Advantages of Cryo-preservation and Formalin Fixation
published pages: Video article, ISSN: 1940-087X, DOI: 10.3791/55885
Journal of Visualized Experiments 130 2020-03-17

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SPIDIA4P" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "SPIDIA4P" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.6.)

SAPHIRE (2018)

Securing Adoption of Personalised Health in REgions

Read More  

GC_1000 (2020)

GROUP CARE FOR THE FIRST 1000 DAYS (GC_1000): If it takes a village to raise a child, group care is the first step

Read More  

PERMIT (2020)

PERsonalised MedicIne Trials

Read More